HYDROSPAN Trademark
Trademark Overview
On Wednesday, December 24, 2025, a trademark application was filed for HYDROSPAN with the United States Patent and Trademark Office. The USPTO has given the HYDROSPAN trademark a serial number of 79444223. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, May 26, 2026. This trademark is owned by Bausch Health Ireland Limited. The HYDROSPAN trademark is filed in the Pharmaceutical Products category with the following description:
pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of autoimmune conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of blood conditions, diseases and disorders; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the prevention and treatment of conditions, diseases, and disorders of the central and peripheral nervous system; pharmaceutical preparations for the prevention and treatment of dermatological conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of endocrine conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of gastrointestinal conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of hepatic conditions, diseases, and disorders; phar...
General Information
| Serial Number | 79444223 |
| Word Mark | HYDROSPAN |
| Filing Date | Wednesday, December 24, 2025 |
| Status | 686 - PUBLISHED FOR OPPOSITION |
| Status Date | Tuesday, May 26, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, May 26, 2026 |
Trademark Statements
| Goods and Services | pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of autoimmune conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of blood conditions, diseases and disorders; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases and disorders; pharmaceutical preparations for the prevention and treatment of conditions, diseases, and disorders of the central and peripheral nervous system; pharmaceutical preparations for the prevention and treatment of dermatological conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of endocrine conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of gastrointestinal conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of hepatic conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of immunological conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of infectious diseases; pharmaceutical preparations for the prevention and treatment of inflammatory conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of metabolic conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of muscular conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of neurological conditions, diseases, and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the prevention and treatment of psychiatric conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of respiratory and pulmonary conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of renal conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of urological conditions, diseases, and disorders; pharmaceutical preparations for the prevention and treatment of viral diseases. |
| Pseudo Mark | HYDRO SPAN |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, February 19, 2026 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Bausch Health Ireland Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 77 - NOT AVAILABLE |
| Address | IE |
| Party Name | Bausch Health Ireland Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 77 - NOT AVAILABLE |
| Address | IE |
Trademark Events
| Event Date | Event Description |
| Thursday, February 19, 2026 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, February 20, 2026 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, February 20, 2026 | APPLICATION FILING RECEIPT MAILED |
| Wednesday, March 11, 2026 | ASSIGNED TO EXAMINER |
| Friday, March 13, 2026 | NON-FINAL ACTION WRITTEN |
| Saturday, March 14, 2026 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Sunday, April 26, 2026 | REFUSAL PROCESSED BY MPU |
| Sunday, April 26, 2026 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Tuesday, April 28, 2026 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, April 28, 2026 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, April 28, 2026 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, April 29, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, May 14, 2026 | REFUSAL PROCESSED BY IB |
| Wednesday, May 20, 2026 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, May 26, 2026 | PUBLISHED FOR OPPOSITION |
| Tuesday, May 26, 2026 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
